Virpax Pharmaceuticals Inc (VRPX)

Virpax Pharmaceuticals Inc. is a healthcare company listed on OTC Markets under the ticker VRPX. The company is described as a preclinical-stage pharmaceutical developer focused on drug-delivery systems and drug-releasing technologies for non-opioid and non-addictive pain management, with an emphasis on central nervous system disorders. Its pipeline includes Epoladerm, a topical spray film technology for osteoarthritis pain; Probudur, an injectable liposomal gel candidate for postoperative pain; and Envelta, a nanotechnology-based intranasal spray designed to deliver a metabolically labile peptide into the brain. Additional preclinical programs include AnQlar, an antiviral barrier intended to help reduce the risk or intensity of certain viral infections, and NobrXiol, an investigational nasal formulation aimed at enhancing cannabidiol transport to the brain. Virpax Pharmaceuticals was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.